Ono Pharmaceutical Co., Ltd. (FRA:ON4)

Germany flag Germany · Delayed Price · Currency is EUR
11.90
-0.30 (-2.46%)
At close: Nov 28, 2025
11.21%
Market Cap5.54B
Revenue (ttm)2.90B
Net Income (ttm)279.29M
Shares Outn/a
EPS (ttm)0.59
PE Ratio19.84
Forward PEn/a
Dividend0.47 (3.95%)
Ex-Dividend DateSep 29, 2025
Volumen/a
Average Volume152
Open12.00
Previous Close12.20
Day's Range11.90 - 12.00
52-Week Range8.95 - 12.20
Betan/a
RSI61.73
Earnings DateFeb 2, 2026

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabet... [Read more]

Industry Pharmaceutical Preparations
Founded 1717
Employees 4,287
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ON4
Full Company Profile

Financial Performance

In 2024, Ono Pharmaceutical's revenue was 486.87 billion, a decrease of -3.14% compared to the previous year's 502.67 billion. Earnings were 50.05 billion, a decrease of -60.89%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.